The IRIS® Registry
Authors:
- D. W.DWD. W.
- F. LumFLF. Lum
- 15 June 2016
- journal article
- leitthema
- Published by Springer Nature in Der Ophthalmologe
- Vol. 114 (S1) , 1-6
Abstract
The American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) launched about 2 years ago and has already become the largest national clinical specialty data registry with nearly 50 million patient visits and over 14 million unique patients. The purpose of the registry is to support and promote continued improvement in the delivery of eye care. The perspectives that “big data” encompass are the key issues facing ophthalmology and eye care, including public health and public policy concerning disease incidence and prevalence, utilization of eye care services, natural history of disease, disease surveillance, comparative effectiveness, safety and adverse event monitoring, compliance with “best practices” and clinical guidelines, etc. The valuable real-world and current-day insights provided by the IRIS Registry and other registries like it will accelerate scientific learning and improvements in care delivery, particularly in a cost-constrained environment.Keywords
This publication has 24 references indexed in Scilit:
- Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programmeBritish Journal of Ophthalmology, 2013
- The Financial Impact of Joint Registries in Identifying Poorly Performing ImplantsThe Journal of Arthroplasty, 2012
- Evidence-based guidelines for cataract surgery: Guidelines based on data in the European Registry of Quality Outcomes for Cataract and Refractive Surgery databaseJournal of Cataract & Refractive Surgery, 2012
- Use Of 13 Disease Registries In 5 Countries Demonstrates The Potential To Use Outcome Data To Improve Health Care’s ValueHealth Affairs, 2012
- Australian and New Zealand Registry of Advanced Glaucoma: methodology and recruitmentClinical & Experimental Ophthalmology, 2011
- One million cataract surgeries: Swedish National Cataract Register 1992–2009Journal of Cataract & Refractive Surgery, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Endophthalmitis after Cataract SurgeryOphthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Initial two years of experience with the AAO National Eyecare Outcomes Network (NEON) cataract surgery database11NEON is a program of the American Academy of Ophthalmology. Covance Health Economics and Outcomes Services Inc. is a consultant to, and provides technical support for, NEON under contract to the AAO.Ophthalmology, 2000